openPR Logo
Press release

Chronic Periodontitis Pipeline 2025: Innovative Clinical Developments from Over 10 Global Leaders - DelveInsight | Highlighting Amyndas Pharmaceuticals, Takeda, CSL Behring, Vaxcyte, Noveome, and Peri

09-25-2025 12:36 AM CET | Associations & Organizations

Press release from: ABNewswire

Chronic Periodontitis Pipeline 2025

Chronic Periodontitis Pipeline 2025

DelveInsight's, "Chronic Periodontitis - Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Periodontitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With chronic periodontitis reaching epidemic levels worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the demand for safer and more effective treatments is rising. DelveInsight reports that over 10 pharmaceutical and biotech companies are actively developing more than 10 therapeutic candidates for chronic periodontitis. These treatments are at various stages of clinical and preclinical development, reflecting significant innovation and dedication to tackling this major public health concern.

DelveInsight's "Chronic Periodontitis Pipeline Insight 2025" offers a comprehensive and strategic analysis of the current R&D landscape. The report examines clinical trial progress, emerging therapies, mechanisms of action, competitive dynamics, and key company initiatives. It serves as an essential resource for stakeholders-including researchers, healthcare investors, and decision-makers-seeking insights into the evolving chronic periodontitis therapeutics market and the advancements shaping its future.

Explore the Cutting-Edge Landscape of Chronic periodontitis Drug Development @ https://www.delveinsight.com/report-store/chronic-periodontitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key Takeaways from the Chronic periodontitis Pipeline Report

*
DelveInsight's chronic periodontitis pipeline report highlights a dynamic landscape, with over 10 active companies developing more than 10 therapeutic candidates for the treatment of chronic periodontitis.

*
In April 2025, researchers at Penn Dental Medicine published in the Journal of Dental Research that an anti-senescence therapy-combining the enzyme inhibitor dasatinib with the natural flavonoid quercetin-reduced markers of cellular senescence, periodontal inflammation, and bone loss in both laboratory and animal models. By targeting cellular senescence, a process in which cells stop dividing and drive chronic inflammation, this approach offers a promising strategy to break the cycle of chronic periodontal disease and enhance both oral and systemic health outcomes.

*
In December 2023, the FDA approved the first clinical trial investigating rapamycin-a drug known for its anti-aging effects-for treating periodontal disease in older adults. Led by Dr. Jonathan An at the University of Washington, the study aims to determine whether targeting the aging process can improve outcomes for periodontal disease, which affects more than 70% of adults over 65.

*
Key players in the chronic periodontitis field, including Amyndas Pharmaceuticals, Takeda, CSL Behring, Vaxcyte, Noveome, Perioc, and others, are actively developing novel therapies to enhance the treatment landscape. Promising pipeline candidates include ST 266 and several others at various stages of development.

Chronic periodontitis Overview:

Periodontal disease and dental caries are the most common oral health conditions. Chronic periodontitis, in particular, is a long-lasting inflammatory disease that affects the soft and hard tissues supporting the teeth and is prevalent worldwide. The condition is associated with biological risk factors such as high blood pressure, elevated cholesterol, diabetes, genetic susceptibility, and obesity, as well as behavioral factors like unhealthy diet, physical inactivity, and tobacco use. Timely detection of chronic periodontitis is essential for effective management.

Download the Chronic periodontitis sample report to know in detail about the Chronic periodontitis treatment market [https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic periodontitis Pipeline Analysis

The Chronic periodontitis pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Chronic periodontitis Market.

*
Categorizes Chronic periodontitis therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Chronic periodontitis drugs under development based on:

*
Stage of development

*
Chronic periodontitis Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Chronic periodontitis Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Chronic periodontitis Licensing agreements

*
Funding and investment activities supporting future Chronic periodontitis market advancement.

Unlock key insights into emerging Chronic periodontitis therapies and market strategies here: https://www.delveinsight.com/report-store/chronic-periodontitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Chronic periodontitis Emerging Drugs

*
ST 266: Noveome

ST266 is a biologic therapy developed from a distinctive population of human amnion-derived cells, produced without including live cells in the final formulation. Through a proprietary culturing technique, these cells release a complex blend of growth factors and cytokines-known as the secretome-that promote cell survival and reduce inflammation.

Chronic periodontitis Pipeline Therapeutic Assessment

Chronic periodontitis Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Chronic periodontitis By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Chronic periodontitis Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Chronic periodontitis Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging Chronic periodontitis therapies and key Chronic periodontitis companies [https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Chronic periodontitis Current Treatment Patterns

4. Chronic periodontitis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Chronic periodontitis Late-Stage Products (Phase-III)

7. Chronic periodontitis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic periodontitis Discontinued Products

13. Chronic periodontitis Product Profiles

14. Chronic periodontitis Key Companies

15. Chronic periodontitis Key Products

16. Dormant and Discontinued Products

17. Chronic periodontitis Unmet Needs

18. Chronic periodontitis Future Perspectives

19. Chronic periodontitis Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Chronic periodontitis pipeline reports offerings [https://www.delveinsight.com/report-store/chronic-periodontitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-periodontitis-pipeline-2025-innovative-clinical-developments-from-over-10-global-leaders-delveinsight-highlighting-amyndas-pharmaceuticals-takeda-csl-behring-vaxcyte-noveome-and-peri]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Periodontitis Pipeline 2025: Innovative Clinical Developments from Over 10 Global Leaders - DelveInsight | Highlighting Amyndas Pharmaceuticals, Takeda, CSL Behring, Vaxcyte, Noveome, and Peri here

News-ID: 4196702 • Views:

More Releases from ABNewswire

TCL Offers Unmatched Discounts on NXTPAPER 11 Gen 2 Tablets for a Limited Time
TCL Offers Unmatched Discounts on NXTPAPER 11 Gen 2 Tablets for a Limited Time
Image: https://www.abnewswire.com/upload/2025/11/7d28d258c990d6d6d333a09d1195a4d9.jpg TCL is making eye comfort more affordable than ever this Black Friday, with both configurations of its NXTPAPER 11 Gen 2 tablet [https://www.amazon.com/dp/B0FG7FRDPL?maas=maas_adg_F465400792B3CDBEB55FE9291F5841A8_afap_abs&ref_=aa_maas&tag=maas] seeing record-low prices on Amazon. From now through December 1, the 64 GB version is down to $159.99 (36% off), and the 128 GB version is just $179.99 (38% off). The NXTPAPER 11 Gen 2 stands out for its paper-like 11-inch Full HD+ display, powered by TCL's
TCL offers exceptional deal making NXTPAPER 11 Plus tablet affordable under 300$
TCL offers exceptional deal making NXTPAPER 11 Plus tablet affordable under 300$
If you're looking for a tablet that balances performance, comfort, and value, the NXTPAPER 11 Plus from TCL [https://www.amazon.com/dp/B0FLJMFNR7?maas=maas_adg_5AF2681E26EC62C74DF5C1C72CE6A9DD_afap_abs&ref_=aa_maas&tag=maas] is shaping up to be one of this year's smartest buys. With the Black Friday sale underway, you can snag it for just $249.99. Image: https://www.abnewswire.com/upload/2025/11/da5f5868666d07b1b589c9593af7a59f.jpg The 11.5" 2.2K resolution screen uses TCL's proprietary NXTPAPER 4.0 technology, designed to reduce glare, cut blue-light emission, and deliver a more "paper-like" reading experience - ideal
TCL Unveils Exceptional Offer on the Advanced NXTPAPER 11 Gen 2 Tablet
TCL Unveils Exceptional Offer on the Advanced NXTPAPER 11 Gen 2 Tablet
If you're on the lookout for an affordable tablet this Black Friday that's easy on the eyes, the TCL NXTPAPER 11 Gen 2 (128 GB) [https://www.amazon.com/dp/B0FG7QV6SF?maas=maas_adg_1486FCD4C758EA9A35182092D196F846_afap_abs&ref_=aa_maas&tag=maas] is now a serious contender - and with its current deal, it's one to watch. Image: https://www.abnewswire.com/upload/2025/11/1c870dfdbb5765161f68d40f15583e4c.jpg Original price: $289.99 Black Friday price: $179.99 - that's 38% off (about $110 off) Deal runs from November 20 through December 1, 2025, available on Amazon. Eye-friendly NXTPAPER display: The NXTPAPER 4.0
Arabian Ranches 2 Dubai Lifestyle and Community Insights
Arabian Ranches 2 Dubai Lifestyle and Community Insights
Image: https://www.abnewswire.com/upload/2025/11/f05e5fe29252be6e415fae48b211f699.jpg Introduction Morning activity sets the tone for the Arabian Ranches 2 lifestyle [https://www.luxuryproperty.com/dubai/villa-for-rent/arabian-ranches-2]. The streets stay calm as joggers move along the shaded paths, and families gather at the parks before school buses arrive. You feel the structure and comfort that define Dubai family communities. Life slows down after you pass the gates. The streets stay organized, and the parks stay active throughout the day. This setting shows the true

All 5 Releases


More Releases for Chronic

Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030 This latest report researches the industry structure,
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991 This latest report researches the
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share
Boot chronic pain
For immediate release Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue. We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them